EST
VRTX icon

EA Series Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

EA Series Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$635K Buy
+1,804
New +$608K 0.02% 748

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EA Series Trust's VRTX Position: Q2 2023 in Review

EA Series Trust opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2023: 1,804 shares worth $635K. The stake represents 0.02% of the portfolio and ranks #748 among its holdings.

1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • EA Series Trust held 1,804 shares of Vertex Pharmaceuticals worth $635K as of Q2 2023.
  • Vertex Pharmaceuticals was a new EA Series Trust position in Q2 2023.
  • Vertex Pharmaceuticals made up 0.02% of EA Series Trust's portfolio in Q2 2023, its #748 holding.
  • 1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.